{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:33:51Z","timestamp":1792802031676,"version":"4.5.0"},"reference-count":383,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2167"],"award-info":[{"award-number":["EXC 2167"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR 2497"],"award-info":[{"award-number":["FOR 2497"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR 2690"],"award-info":[{"award-number":["FOR 2690"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RI\/1056-11,"],"award-info":[{"award-number":["RI\/1056-11,"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1526"],"award-info":[{"award-number":["SFB 1526"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR071653"],"award-info":[{"award-number":["R01AR071653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR076766"],"award-info":[{"award-number":["R01AR076766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["CRSII5_202301\/1"],"award-info":[{"award-number":["CRSII5_202301\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>An estimated 20\u201325% of the population is affected by chronic, non-communicable inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors. Autoimmunity is another important cause of chronic skin inflammation. The autoimmune response may be mainly T cell driven, such as in alopecia areata or vitiligo, or B cell driven in chronic spontaneous urticaria, pemphigus and pemphigoid diseases. Rare causes of chronic skin inflammation are autoinflammatory diseases, or rheumatic diseases, such as cutaneous lupus erythematosus or dermatomyositis. Whilst we have seen a significant improvement in diagnosis and treatment, several challenges remain. Especially for rarer causes of chronic skin inflammation, early diagnosis is often missed because of low awareness and lack of diagnostics. Systemic immunosuppression is the treatment of choice for almost all of these diseases. Adverse events due to immunosuppression, insufficient therapeutic responses and relapses remain a challenge. For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed. Given the encouraging developments during the past years, we envision that many of these challenges in the diagnosis and treatment of chronic inflammatory skin diseases will be thoroughly addressed in the future.<\/jats:p>","DOI":"10.3389\/fmed.2022.875492","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T02:30:51Z","timestamp":1654741851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":148,"title":["Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases"],"prefix":"10.3389","volume":"9","author":[{"given":"Hideyuki","family":"Ujiie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Boch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Thaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle T.","family":"Amber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Recke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Gra\u00dfhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Hackel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gant","family":"Sprow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Sezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Christiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalaf","family":"Kridin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jaci.2018.02.044","article-title":"TH1\/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus","volume":"142","author":"Schmidt","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J Exp Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/jdv.15339","article-title":"Severity, heterogeneity and systemic inflammation in psoriasis","volume":"33","author":"Christophers","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/jamadermatol.2019.3308","article-title":"Prevalence of pemphigoid as a potentially unrecognized cause of pruritus in nursing home residents","volume":"155","author":"Meijer","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: global epidemiology and risk factors","volume":"66","author":"Nutten","year":"2015","journal-title":"Ann Nutr Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"adv00160","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: a systematic review","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e39803","DOI":"10.1371\/journal.pone.0039803","article-title":"Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies","volume":"7","author":"Deckers","year":"2012","journal-title":"PLoS ONE."},{"key":"B9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjd.19169","article-title":"Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender","volume":"184","author":"Iskandar","year":"2021","journal-title":"Br J Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"adv00309","DOI":"10.2340\/00015555-3655","article-title":"Epidemiology of prurigo nodularis compared with psoriasis in germany: a claims database analysis","volume":"100","author":"St\u00e4nder","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jdin.2020.10.009","article-title":"Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis","volume":"2","author":"St\u00e4nder","year":"2021","journal-title":"JAAD Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"737813","DOI":"10.3389\/fmed.2021.737813","article-title":"Lichen planus","volume":"8","author":"Boch","year":"2021","journal-title":"Front Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMcp1103641","article-title":"Clinical practice. Lichen planus","volume":"366","author":"Le Cleach","year":"2012","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1111\/jdv.16783","article-title":"Hidradenitis suppurativa - prevalence analyses of German statutory health insurance data","volume":"35","author":"Schneider-Burrus","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1203475420972348","article-title":"Race-Specific prevalence of hidradenitis suppurativa","volume":"25","author":"Sachdeva","year":"2021","journal-title":"J Cutan Med Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/1346-8138.15811","article-title":"Epidemiology of hidradenitis suppurativa in Taiwan: a 14-year nationwide population-based study","volume":"48","author":"Liang","year":"2021","journal-title":"J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0163806","DOI":"10.1371\/journal.pone.0163806","article-title":"The prevalence of vitiligo: a meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS ONE."},{"key":"B21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.xjidi.2021.100004","article-title":"Epidemiology of pemphigus","volume":"1","author":"Kridin","year":"2021","journal-title":"JID Innov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany","volume":"136","author":"H\u00fcbner","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","article-title":"Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations","volume":"66","author":"Kridin","year":"2017","journal-title":"Immunol Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/jid.2011.231","article-title":"Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita","volume":"131","author":"Zumelzu","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/ard.2010.138420","article-title":"Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France","volume":"70","author":"Cuisset","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/jpc.13270","article-title":"Cryopyrin-associated periodic syndrome in Australian children and adults: epidemiological, clinical and treatment characteristics","volume":"52","author":"Mehr","year":"2016","journal-title":"J Paediatr Child Health."},{"key":"B29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/all.12129","article-title":"Schnitzler's syndrome: diagnosis, treatment, and follow-up","volume":"68","author":"Simon","year":"2013","journal-title":"Allergy."},{"key":"B30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13023-019-1117-2","article-title":"Schnitzler's syndrome - a novel hypothesis of a shared pathophysiologic mechanism with Waldenstr\u00f6m's disease","volume":"14","author":"van Leersum","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2147\/JMDH.S179623","article-title":"A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach","volume":"12","author":"Jarrett","year":"2019","journal-title":"J Multidiscip Healthc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1177\/0961203316651745","article-title":"Ethnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand","volume":"25","author":"Jarrett","year":"2016","journal-title":"Lupus."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24786.","article-title":"Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study","author":"Kronzer","year":"2021","journal-title":"Arthritis Care Res."},{"key":"B34","unstructured":"GoonesekeraS BansalA TadwalkarS IsherwoodA The Prevalence of Systemic Sclerosis, Dermatomyositis\/Polymyositis, Giant Cell Arteritis in the United States by Race Ethnicity: An Analysis Using Electronic Health Records2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","article-title":"Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis","volume":"60","author":"Bairkdar","year":"2021","journal-title":"Rheumatology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40257-019-00453-7","article-title":"Adult-Onset atopic dermatitis: characteristics and management","volume":"20","author":"Vakharia","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/jdv.12154","article-title":"Quality of health care of atopic eczema in Germany: results of the national health care study atopichealth","volume":"28","author":"Langenbruch","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/jid.2014.70","article-title":"Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study","volume":"134","author":"Halvorsen","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.anai.2019.07.008","article-title":"A real-world study evaluating adeQUacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment","volume":"123","author":"Wei","year":"2019","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2340\/00015555-3102","article-title":"Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European countries","volume":"99","author":"Zink","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","article-title":"Atopic dermatitis: pathophysiology","volume":"1027","author":"David Boothe","year":"2017","journal-title":"Adv Exp Med Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/all.13228","article-title":"Is the atopic march related to confounding by genetics and early-life environment? A systematic review of sibship and twin data","volume":"73","author":"Khan","year":"2018","journal-title":"Allergy."},{"key":"B43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1038\/jid.2008.29","article-title":"Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum","volume":"128","author":"Kezic","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah4680","article-title":"Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis","author":"Nakatsuji","year":"2017","journal-title":"Sci Transl Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1101\/gr.131029.111","article-title":"Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis","volume":"22","author":"Kong","year":"2012","journal-title":"Genome Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/09546634.2019.1655137","article-title":"Atopic dermatitis epidemiology and unmet need in the United Kingdom","volume":"31","author":"Cork","year":"2020","journal-title":"J Dermatolog Treat."},{"key":"B48","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1468-3083.2006.01664.x","article-title":"Comparative efficacy of Hanifin and Rajka's criteria and the UK working party's diagnostic criteria in diagnosis of atopic dermatitis in a hospital setting in North India","volume":"20","author":"De","year":"2006","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/all.12112","article-title":"Characterization of different courses of atopic dermatitis in adolescent and adult patients","volume":"68","author":"Garmhausen","year":"2013","journal-title":"Allergy."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaci.2018.06.016","article-title":"Atopic dermatitis in Chinese patients shows TH2\/TH17 skewing with psoriasiform features","volume":"142","author":"Chan","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/all.12685","article-title":"Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies","volume":"70","author":"Silverberg","year":"2015","journal-title":"Allergy."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1365-2133.2010.09887.x","article-title":"Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U","volume":"163","author":"Arana","year":"2010","journal-title":"Br J Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go","volume":"139","author":"Bieber","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1398-9995.2008.01683.x","article-title":"Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment","volume":"63","author":"Wollenberg","year":"2008","journal-title":"Allergy."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2020.2240","article-title":"Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis","volume":"156","author":"Asgari","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","article-title":"New and emerging systemic treatments for atopic dermatitis","volume":"80","author":"Newsom","year":"2020","journal-title":"Drugs."},{"key":"B60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","article-title":"New treatments in atopic dermatitis","volume":"126","author":"Puar","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/pharmaceutics13071064","article-title":"Therapeutic development based on the immunopathogenic mechanisms of psoriasis","volume":"13","author":"Tseng","year":"2021","journal-title":"Pharmaceutics."},{"key":"B62","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet."},{"key":"B64","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","article-title":"The interleukin-23\/Interleukin-17 axis links adaptive and innate immunity in psoriasis","volume":"9","author":"Sch\u00f6n","year":"2018","journal-title":"Front Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3389\/fimmu.2019.01764","article-title":"Adaptive and innate immunity in psoriasis and other inflammatory disorders","volume":"10","author":"Sch\u00f6n","year":"2019","journal-title":"Front Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/ddg.14508","article-title":"German S3-guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: treatment goals and treatment recommendations","volume":"19","author":"Nast","year":"2021","journal-title":"J Dtsch Dermatol Ges."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/ddg.14507","article-title":"German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm\u2014part 2: treatment monitoring and specific clinical or comorbid situations","volume":"19","author":"Nast","year":"2021","journal-title":"J Dtsch Dermatol Ges."},{"key":"B69","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","article-title":"Comparative Efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"11","author":"Armstrong","year":"2021","journal-title":"Dermatol Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12788\/cutis.0317","article-title":"Update on biologics for psoriasis in clinical practice","volume":"108","author":"Ivanic","year":"2021","journal-title":"Cutis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2217\/imt-2020-0292","article-title":"Immunotherapy in psoriasis","volume":"13","author":"Landeck","year":"2021","journal-title":"Immunotherapy."},{"key":"B72","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub4","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"4","author":"Sbidian","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/BTT.S290309","article-title":"Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules","volume":"15","author":"Bellinato","year":"2021","journal-title":"Biologics."},{"key":"B74","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/ddg.13907","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents - short version part 1","volume":"17","author":"Eisert","year":"2019","journal-title":"J Dtsch Dermatol Ges."},{"key":"B75","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/ddg.13936","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents - short version part 2","volume":"17","author":"Eisert","year":"2019","journal-title":"J Dtsch Dermatol Ges."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e13000","DOI":"10.1111\/sji.13000","article-title":"The attentive focus on T cell-mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo","volume":"93","author":"Aghamajidi","year":"2021","journal-title":"Scand J Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaci.2020.05.009","article-title":"Mechanisms of skin autoimmunity: cellular and soluble immune components of the skin","volume":"146","author":"Gudjonsson","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"696597","DOI":"10.3389\/fmed.2021.696597","article-title":"Systematic review and recommendations to combine newer therapies with conventional therapy in psoriatic disease","volume":"8","author":"Arora","year":"2021","journal-title":"Front Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.3390\/jcm10153199","article-title":"Molecular pathogenesis of psoriasis and biomarkers reflecting disease activity","volume":"10","author":"Honma","year":"2021","journal-title":"J Clin Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1759720X211014010","DOI":"10.1177\/1759720X211014010","article-title":"Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review","volume":"13","author":"Magee","year":"2021","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s40265-021-01612-z","article-title":"Bimekizumab for the treatment of psoriasis","volume":"81","author":"Freitas","year":"2021","journal-title":"Drugs."},{"key":"B82","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/ddg.14124","article-title":"Cytokines of the IL-17 family in psoriasis","volume":"18","author":"Lauffer","year":"2020","journal-title":"J Dtsch Dermatol Ges."},{"key":"B83","doi-asserted-by":"publisher","first-page":"8076","DOI":"10.3390\/ijms22158076","article-title":"Mast cell cytokines IL-1, IL-33, and IL-36 mediate skin inflammation in psoriasis: a novel therapeutic approach with the anti-inflammatory cytokines IL-37, IL-38, and IL-1Ra","volume":"22","author":"Conti","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/ijms22094344","article-title":"Exploring the role of IL-36 cytokines as a new target in psoriatic disease","volume":"22","author":"Iznardo","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaci.2021.08.010","article-title":"The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions","volume":"148","author":"Fragoulis","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.3390\/jcm10194307","article-title":"Role of janus kinase inhibitors in therapy of psoriasis","volume":"10","author":"S\u0142uczanowska-G\u0142abowska","year":"2021","journal-title":"J Clin Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2019.01.001","article-title":"Emerging role of immune cell network in autoimmune skin disorders: an update on pemphigus, vitiligo and psoriasis","volume":"45","author":"Das","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"B88","doi-asserted-by":"publisher","first-page":"649332","DOI":"10.3389\/fmed.2021.649332","article-title":"Chronic prurigo: similar clinical profile and burden across clinical phenotypes","volume":"8","author":"Zeidler","year":"2021","journal-title":"Front Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.14570","article-title":"European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"adv00155","DOI":"10.2340\/00015555-3518","article-title":"Prevalence of prurigo nodularis in Poland","volume":"100","author":"Ryczek","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1111\/jdv.17485","article-title":"Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: a population-based claims data analysis","volume":"35","author":"Augustin","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","article-title":"Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis","volume":"14","author":"Williams","year":"2021","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"107472","DOI":"10.1016\/j.celrep.2020.03.036","article-title":"Periostin activation of integrin receptors on sensory neurons induces allergic itch","volume":"31","author":"Mishra","year":"2020","journal-title":"Cell Rep."},{"key":"B96","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jid.2019.05.029","article-title":"Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus","volume":"140","author":"Pogatzki-Zahn","year":"2020","journal-title":"J Invest Dermatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/exd.13343","article-title":"There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations","volume":"26","author":"Pereira","year":"2017","journal-title":"Exp Dermatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1097\/itx.0000000000000042","article-title":"IFSI-guideline on chronic prurigo including prurigo nodularis","volume":"5","author":"St\u00e4nder","year":"2020","journal-title":"Itch."},{"key":"B99","doi-asserted-by":"publisher","first-page":"adv00401","DOI":"10.2340\/00015555-3701","article-title":"Investigator's global assessment of chronic prurigo: a new instrument for use in clinical trials","volume":"101","author":"Zeidler","year":"2021","journal-title":"Acta Derm Venereol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/jdv.15040","article-title":"Prurigo activity score (PAS): validity and reliability of a new instrument to monitor chronic prurigo","volume":"32","author":"P\u00f6lking","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamadermatol.2020.3071","article-title":"Validation of psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: a secondary analysis of a randomized clinical trial","volume":"156","author":"Kimel","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/jdv.15225","article-title":"Cross-European validation of the ItchyQoL in pruritic dermatoses","volume":"33","author":"Zeidler","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"adv00403","DOI":"10.2340\/00015555-3726","article-title":"Chronic nodular prurigo: a european cross-sectional study of patient perspectives on therapeutic goals and satisfaction","volume":"101","author":"Pereira","year":"2021","journal-title":"Acta Derm Venereol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14712598.2021.1958777","article-title":"Therapeutic potential of biologics in prurigo nodularis","volume":"22","author":"M\u00fcller","year":"2021","journal-title":"Expert Opin Biol Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/ddg.14107","article-title":"Dupilumab for treatment-refractory prurigo nodularis","volume":"18","author":"Kov\u00e1cs","year":"2020","journal-title":"J Dtsch Dermatol Ges."},{"key":"B106","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0190-9622(91)70241-S","article-title":"Lichen planus","volume":"25","author":"Boyd","year":"1991","journal-title":"J Am Acad Dermatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/ddg.14565","article-title":"Lichen planus - a clinical guide","volume":"19","author":"Solimani","year":"2021","journal-title":"J Dtsch Dermatol Ges."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3389\/fimmu.2019.01389","article-title":"Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering","volume":"10","author":"H\u00fcbner","year":"2019","journal-title":"Front Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3389\/fimmu.2019.01808","article-title":"Therapeutic targeting of Th17\/Tc17 cells leads to clinical improvement of lichen planus","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3389\/fimmu.2018.00779","article-title":"Humoral epitope spreading in autoimmune bullous diseases","volume":"9","author":"Didona","year":"2018","journal-title":"Front Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaad.2010.03.029","article-title":"Lichen planus of the esophagus: what dermatologists need to know","volume":"65","author":"Fox","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"652","DOI":"10.5858\/2008-132-652-ID","article-title":"Interface dermatitis","volume":"132","author":"Crowson","year":"2008","journal-title":"Arch Pathol Lab Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"E2178","DOI":"10.3390\/ijms21062178","article-title":"Paraneoplastic dermatoses: a brief general review and an extensive analysis of paraneoplastic pemphigus and paraneoplastic dermatomyositis","volume":"21","author":"Didona","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/ajd.13350","article-title":"Forming diagnostic criteria for vulvar lichen planus","volume":"61","author":"Wu","year":"2020","journal-title":"Austral J Dermatol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/jdv.16464","article-title":"European S1 guidelines on the management of lichen planus: a cooperation of the european dermatology forum with the european academy of dermatology and venereology","volume":"34","author":"Ioannides","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/s41598-020-58548-9","article-title":"Photodynamic therapy in oral lichen planus: a prospective case-controlled pilot study","volume":"10","author":"Cosgarea","year":"2020","journal-title":"Sci Rep."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.jaci.2020.01.031","article-title":"Treatment of severe lichen planus with the JAK inhibitor tofacitinib","volume":"145","author":"Damsky","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/ddg.12141","article-title":"Individualizing treatment and choice of medication in lichen planus: a step by step approach","volume":"11","author":"Manousaridis","year":"2013","journal-title":"J Dtsch Dermatol Ges."},{"key":"B119","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B120","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","article-title":"Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system","volume":"236","author":"Kokolakis","year":"2020","journal-title":"Dermatology."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e31810","DOI":"10.1371\/journal.pone.0031810","article-title":"Increased prevalence of metabolic syndrome in patients with acne inversa","volume":"7","author":"Sabat","year":"2012","journal-title":"PLoS ONE."},{"key":"B122","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/ddg.12067","article-title":"Depression is a frequent co-morbidity in patients with acne inversa","volume":"11","author":"Kurek","year":"2013","journal-title":"J Dtsch Dermatol Ges."},{"key":"B123","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jdv.12567","article-title":"Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa","volume":"29","author":"Shavit","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1159\/000448838","article-title":"High prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa","volume":"232","author":"Schneider-Burrus","year":"2016","journal-title":"Dermatology."},{"key":"B125","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2133.2009.09430.x","article-title":"Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study","volume":"162","author":"van der Zee","year":"2010","journal-title":"Br J Dermatol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2340\/00015555-0866","article-title":"Psychophysical aspects of hidradenitis suppurativa","volume":"90","author":"Matusiak","year":"2010","journal-title":"Acta Derm Venereol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamadermatol.2017.6058","article-title":"Association of hidradenitis suppurativa with body image","volume":"154","author":"Schneider-Burrus","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","article-title":"Increased suicide risk in patients with hidradenitis suppurativa","volume":"138","author":"Thorlacius","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/jdv.16224","article-title":"Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the US FDA adverse events reporting system pharmacovigilance database","volume":"34","author":"Gupta","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/bjd.17578","article-title":"Substantially reduced life expectancy in patients with hidradenitis suppurativa: a finnish nationwide registry study","volume":"180","author":"Tiri","year":"2019","journal-title":"Br J Dermatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the international hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"676241","DOI":"10.3389\/fmed.2021.676241","article-title":"Features associated with quality of life impairment in hidradenitis suppurativa patients","volume":"8","author":"Schneider-Burrus","year":"2021","journal-title":"Front Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/jdv.17148","article-title":"Convergent validity of suffering and quality of life as measured by the hidradenitis suppurativa quality of life","volume":"35","author":"Kursawe Larsen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000517412","article-title":"Hidradenitis suppurativa in a large cohort of italian patients: evaluation of the burden of disease","volume":"238","author":"Fabbrocini","year":"2021","journal-title":"Dermatology"},{"key":"B135","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/13547500903075218","article-title":"Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging","volume":"14","author":"Matusiak","year":"2009","journal-title":"Biomarkers."},{"key":"B136","doi-asserted-by":"publisher","first-page":"4097574","DOI":"10.1155\/2016\/4097574","article-title":"MMP8 is increased in lesions and blood of acne inversa patients: a potential link to skin destruction and metabolic alterations","volume":"2016","author":"Tsaousi","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/bjd.15424","article-title":"Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa\/hidradenitis suppurativa","volume":"177","author":"Wolk","year":"2017","journal-title":"Br J Dermatol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1016\/j.jid.2020.04.011","article-title":"Lipidomics profiling of hidradenitis suppurativa skin lesions reveals lipoxygenase pathway dysregulation and accumulation of proinflammatory leukotriene B4","volume":"140","author":"Penno","year":"2020","journal-title":"J Invest Dermatol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bjd.19795","article-title":"Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa","volume":"185","author":"Wolk","year":"2021","journal-title":"Br J Dermatol."},{"key":"B143","first-page":"751","article-title":"Alopecia areata: part 1: pathogenesis, diagnosis, and prognosis","volume":"61","author":"Spano","year":"2015","journal-title":"Can Fam Phys."},{"key":"B144","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1046\/j.1365-2133.2003.05535.x","article-title":"Guidelines for the management of alopecia areata","volume":"149","author":"MacDonald Hull","year":"2003","journal-title":"Br J Dermatol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/ijd.13866","article-title":"Nail changes in alopecia areata: an update and review","volume":"57","author":"Chelidze","year":"2018","journal-title":"Int J Dermatol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"609","DOI":"10.23736\/S0392-0488.19.06458-7","article-title":"Italian guidelines in diagnosis and treatment of alopecia areata","volume":"154","author":"Rossi","year":"2019","journal-title":"G Ital Dermatol Venereol."},{"key":"B147","first-page":"308","article-title":"Overview of alopecia: a dermatopathologist's perspective","volume":"112","author":"Vidal","year":"2015","journal-title":"Mo Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1529-8019.2011.01414.x","article-title":"Histopathology of alopecia areata, acute and chronic: why is it important to the clinician","volume":"24","author":"Dy","year":"2011","journal-title":"Dermatol Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0974-7753.66920","article-title":"Intralesional steroids for alopecia areata","volume":"2","author":"Kumaresan","year":"2010","journal-title":"Int J Trichol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2004.10.873","article-title":"Placebo-controlled oral pulse prednisolone therapy in alopecia areata","volume":"52","author":"Kar","year":"2005","journal-title":"J Am Acad Dermatol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-4362.1996.tb03281.x","article-title":"Pulsed administration of corticosteroids in the treatment of alopecia areata","volume":"35","author":"Sharma","year":"1996","journal-title":"Int J Dermatol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4161\/derm.1.6.11236","article-title":"Medium-dose prednisolone pulse therapy in alopecia areata","volume":"1","author":"Efentaki","year":"2009","journal-title":"Dermatoendocrinology."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/archderm.1976.01630350025006","article-title":"Prednisone therapy for alopecia areata. A follow-up report","volume":"112","author":"Winter","year":"1976","journal-title":"Arch Dermatol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0190-9622(91)70037-3","article-title":"Treatment of alopecia areata with diphenylcyclopropenone","volume":"24","author":"van der Steen","year":"1991","journal-title":"J Am Acad Dermatol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S0190-9622(98)70048-9","article-title":"Efficacy of topical sensitizers in the treatment of alopecia areata","volume":"39","author":"Rokhsar","year":"1998","journal-title":"J Am Acad Dermatol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1600-0536.1989.tb04737.x","article-title":"Contact urticaria during topical immunotherapy","volume":"21","author":"Tosti","year":"1989","journal-title":"Contact Dermatitis."},{"key":"B157","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2133.1995.tb02692.x","article-title":"Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis","volume":"133","author":"Henderson","year":"1995","journal-title":"Br J Dermatol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PROM.S62879","article-title":"Impact of tofacitinib on patient outcomes in rheumatoid arthritis - review of clinical studies","volume":"7","author":"Boyce","year":"2016","journal-title":"Pat Relat Outcome Meas."},{"key":"B162","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jaad.2009.02.006","article-title":"Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors","volume":"62","author":"Rodriguez","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"B166","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet."},{"key":"B167","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14728214.2020.1712358","article-title":"Emerging drugs for the treatment of vitiligo","volume":"25","author":"Karagaiah","year":"2020","journal-title":"Expert Opin Emerg Drugs."},{"key":"B168","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/bjd.19164","article-title":"Reliability and validity of the vitiligo signs of activity score","volume":"183","author":"Eleftheriadou","year":"2020","journal-title":"Br J Dermatol."},{"key":"B169","first-page":"189","article-title":"Vitiligo: to biopsy or not to biopsy","volume":"105","author":"Mazzei Weiss","year":"2020","journal-title":"Cutis."},{"key":"B170","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the European dermatology forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for vitiligo: a systematic review and meta-analysis","volume":"153","author":"Bae","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3892\/etm.2021.10229","article-title":"Updates and new medical treatments for vitiligo (review)","volume":"22","author":"Kubelis-L\u00f3pez","year":"2021","journal-title":"Exp Ther Med."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/ijd.14055","article-title":"Comorbidities in vitiligo: comprehensive review","volume":"57","author":"Dahir","year":"2018","journal-title":"Int J Dermatol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet."},{"key":"B178","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2021","journal-title":"Allergy."},{"key":"B179","doi-asserted-by":"publisher","first-page":"100533","DOI":"10.1016\/j.waojou.2021.100533","article-title":"The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management","volume":"14","author":"S\u00e1nchez-Borges","year":"2021","journal-title":"World Allergy Organ J."},{"key":"B180","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.jaip.2021.03.049","article-title":"The diagnostic workup in chronic spontaneous urticaria-what to test and why","volume":"9","author":"Metz","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guill\u00e9n-Aguinaga","year":"2016","journal-title":"Br J Dermatol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jaip.2019.01.026","article-title":"Relevance of the basophil high-affinity ige receptor in chronic urticaria: clinical experience from a tertiary care institution","volume":"7","author":"Deza","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B184","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-021-00622-y","article-title":"Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases","volume":"22","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5414\/ALX02204E","article-title":"Use of biologics in chronic spontaneous urticaria - beyond omalizumab therapy","volume":"5","author":"Metz","year":"2021","journal-title":"Allergol Select."},{"key":"B186","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.anai.2019.08.465","article-title":"Current and emerging treatments for chronic spontaneous urticaria","volume":"125","author":"Johal","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med."},{"key":"B188","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00281-015-0541-1","article-title":"Immune response in pemphigus and beyond: progresses and emerging concepts","volume":"38","author":"Di Zenzo","year":"2016","journal-title":"Semin Immunopathol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B190","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet."},{"key":"B191","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/jop.13052","article-title":"Clinical presentation and diagnostic delay in pemphigus vulgaris: a prospective study from Turkey","volume":"49","author":"Daltaban","year":"2020","journal-title":"J Oral Pathol Med."},{"key":"B192","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/DAD.0000000000001817","article-title":"Immunoglobulin and complement immunohistochemistry on paraffin sections in autoimmune bullous diseases: a systematic review and meta-analysis","volume":"43","author":"Kasperkiewicz","year":"2021","journal-title":"Am J Dermatopathol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/odi.13849","article-title":"ELISA detection of anti-desmoglein 1 and anti-desmoglein 3 and indirect immunofluorescence in oral pemphigus: a retrospective study","volume":"28","author":"Petruzzi","year":"2021","journal-title":"Oral Dis"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs."},{"key":"B195","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B196","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1056\/NEJMc2111763","article-title":"Rituximab versus mycophenolate mofetil in pemphigus vulgaris. Reply","volume":"385","author":"Werth","year":"2021","journal-title":"N Engl J Med."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/ijdvl.IJDVL_848_17","article-title":"Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: a retrospective single-center review of up to 68 months follow-up","volume":"86","author":"De","year":"2020","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jaad.2020.06.024","article-title":"The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: daily practice data from a retrospective study","volume":"83","author":"Rashid","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/ijd.14143","article-title":"Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs","volume":"58","author":"Grando","year":"2019","journal-title":"Int J Dermatol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1172\/JCI60139","article-title":"Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering","volume":"123","author":"Spindler","year":"2013","journal-title":"J Clin Invest."},{"key":"B203","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1111\/bph.15233","article-title":"Identification of novel therapeutic targets for blocking acantholysis in pemphigus","volume":"177","author":"Burmester","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3389\/fimmu.2018.01190","article-title":"Non-Desmoglein antibodies in patients with pemphigus vulgaris","volume":"9","author":"Amber","year":"2018","journal-title":"Front Immunol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/bjd.20091","article-title":"Ca2+ signalling is critical for autoantibody-induced blistering of human epidermis in pemphigus","volume":"185","author":"Schmitt","year":"2021","journal-title":"Br J Dermatol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"701809","DOI":"10.3389\/fmed.2021.701809","article-title":"Autoantibody-Specific signalling in pemphigus","volume":"8","author":"Schmitt","year":"2021","journal-title":"Front Med."},{"key":"B207","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet."},{"key":"B208","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/1346-8138.15912","article-title":"Prevalence and presumptive triggers of localized bullous pemphigoid","volume":"48","author":"St\u00e4nder","year":"2021","journal-title":"J Dermatol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fimmu.2018.00542","article-title":"Bullous pemphigoid triggered by thermal burn under medication with a dipeptidyl peptidase-iv inhibitor: a case report and review of the literature","volume":"9","author":"Mai","year":"2018","journal-title":"Front Immunol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.jaci.2018.03.014","article-title":"Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects","volume":"142","author":"Muramatsu","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the french pharmacovigilance database","volume":"175","author":"B\u00e9n","year":"2016","journal-title":"Br J Dermatol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.2337\/dc18-0210","article-title":"Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the japanese adverse drug event report database","volume":"41","author":"Arai","year":"2018","journal-title":"Diabetes Care."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the european dermatology forum consensus in collaboration with the european academy of dermatology and venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J Dermatol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaad.2017.10.035","article-title":"Nonbullous pemphigoid: a systematic review","volume":"78","author":"Lamberts","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2340\/00015555-3052","article-title":"Unmet needs in pemphigoid diseases: an international survey amongst patients, clinicians and researchers","volume":"99","author":"Lamberts","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/1346-8138.15816","article-title":"Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment","volume":"48","author":"Ujiie","year":"2021","journal-title":"J Dermatol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet."},{"key":"B224","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","article-title":"Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study","volume":"150","author":"Fichel","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jaad.2020.02.058","article-title":"Bullous pemphigoid: rituximab to the rescue [editorial]","volume":"82","author":"Heymann","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B226","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjd.19890","article-title":"Mortality and clinical response of patients with bullous pemphigoid treated with rituximab","volume":"185","author":"Yoo","year":"2021","journal-title":"Br J Dermatol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J Invest Dermatol."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","article-title":"IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice","volume":"127","author":"Zone","year":"2007","journal-title":"J Invest Dermatol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4049\/jimmunol.1001753","article-title":"FcR-Independent effects of IgE and IgG autoantibodies in bullous pemphigoid","volume":"187","author":"Messingham","year":"2011","journal-title":"J Immunol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3389\/fimmu.2019.01919","article-title":"Effects of omalizumab on Fc\u03b5RI and IgE expression in lesional skin of bullous pemphigoid","volume":"10","author":"Seyed Jafari","year":"2019","journal-title":"Front Immunol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol."},{"key":"B235","doi-asserted-by":"publisher","first-page":"103036","DOI":"10.1016\/j.autrev.2022.103036","article-title":"Mucous membrane pemphigoid","volume":"21","author":"Du","year":"2022","journal-title":"Autoimmun Rev."},{"key":"B236","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamadermatol.2021.4773","article-title":"Evaluation of site- and autoantigen-specific characteristics of mucous membrane pemphigoid","volume":"158","author":"van Beek","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous diseases french study group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J Dtsch Dermatol Ges."},{"key":"B240","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/jdv.16467","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases among paediatric patients in Germany","volume":"34","author":"H\u00fcbner","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/jdv.17397","article-title":"European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology - part I","volume":"35","author":"Rashid","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jdv.17395","article-title":"European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology - part II","volume":"35","author":"Schmidt","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2017.05.016","article-title":"Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid","volume":"77","author":"Shimanovich","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B244","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmed.2018.00020","article-title":"Direct immunofluorescence using non-lesional buccal mucosa in mucous membrane pemphigoid","volume":"5","author":"Kamaguchi","year":"2018","journal-title":"Front Med."},{"key":"B245","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3238\/arztebl.m2021.0136","article-title":"Bullous autoimmune dermatoses","volume":"118","author":"van Beek","year":"2021","journal-title":"Dtsch Arztebl Int."},{"key":"B246","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/ddg.13637","article-title":"Diagnosis of autoimmune bullous diseases","volume":"16","author":"van Beek","year":"2018","journal-title":"J Dtsch Dermatol Ges."},{"key":"B247","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fmed.2018.00296","article-title":"Diagnosis of autoimmune blistering diseases","volume":"5","author":"Witte","year":"2018","journal-title":"Front Med"},{"key":"B248","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1365-2133.2012.10820.x","article-title":"Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid","volume":"166","author":"Blocker","year":"2012","journal-title":"Br J Dermatol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/bjd.17202","article-title":"A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid","volume":"180","author":"Goletz","year":"2019","journal-title":"Br J Dermatol."},{"key":"B250","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1111\/j.1468-3083.2012.04617.x","article-title":"Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions","volume":"27","author":"Kim","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B251","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.jaad.2011.12.032","article-title":"Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita","volume":"68","author":"Komorowski","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1600-0625.2007.00592.x","article-title":"Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies","volume":"16","author":"Sitaru","year":"2007","journal-title":"Exp Dermatol."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archderm.135.9.1091","article-title":"Antiepiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases","volume":"135","author":"Leverkus","year":"1999","journal-title":"Arch Dermatol."},{"key":"B254","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","article-title":"Anti-epiligrin cicatricial pemphigoid and relative risk for cancer","volume":"357","author":"Egan","year":"2001","journal-title":"Lancet."},{"key":"B255","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1346-8138.2004.tb00497.x","article-title":"A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy","volume":"31","author":"Matsushima","year":"2004","journal-title":"J Dermatol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1365-2133.2011.10474.x","article-title":"Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 dutch patients","volume":"165","author":"Terra","year":"2011","journal-title":"Br J Dermatol."},{"key":"B257","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.4049\/jimmunol.159.5.2484","article-title":"Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile","volume":"159","author":"Kitagaki","year":"1997","journal-title":"J Immunol."},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4104.","article-title":"Anti-laminin 332 antibody detection using biochip immunofluorescence microscopy in a real-life cohort of Italian patients with mucous membrane pemphigoid","author":"Gasparini","year":"2021","journal-title":"Eur J Dermatol."},{"key":"B259","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/bjd.20099","article-title":"Clinical and immunological findings in 55 patients with anti-laminin 332-type mucous membrane pemphigoid","volume":"185","author":"Li","year":"2021","journal-title":"Br J Dermatol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2013.1434","article-title":"Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid","volume":"149","author":"Bernard","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B261","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc."},{"key":"B262","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.jid.2017.03.037","article-title":"Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease","volume":"137","author":"Heppe","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1172\/JCI118942","article-title":"Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice","volume":"98","author":"Lazarova","year":"1996","journal-title":"J Clin Invest."},{"key":"B264","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.jid.2021.04.009","article-title":"Dapsone suppresses disease in preclinical murine models of pemphigoid diseases","volume":"141","author":"Murthy","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B265","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.autrev.2019.06.007","article-title":"Epidermolysis bullosa acquisita: a comprehensive review","volume":"18","author":"Kridin","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B266","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fmed.2018.00362","article-title":"Epidermolysis bullosa acquisita: The 2019 update","volume":"5","author":"Koga","year":"2019","journal-title":"Front Med."},{"key":"B267","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/1744666X.2016.1221343","article-title":"Clinical features and diagnosis of epidermolysis bullosa acquisita","volume":"13","author":"Vorobyev","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B268","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1111\/jdv.16676","article-title":"Gastrointestinal involvement of primary skin diseases","volume":"34","author":"Lu","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B269","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jaad.2017.11.029","article-title":"Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases","volume":"78","author":"Meijer","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"B271","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2340\/00015555-1065","article-title":"Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases","volume":"91","author":"Kim","year":"2011","journal-title":"Acta Derm Venereol."},{"key":"B272","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41467-020-20604-3","article-title":"Granzyme B inhibition reduces disease severity in autoimmune blistering diseases","volume":"12","author":"Hiroyasu","year":"2021","journal-title":"Nat Commun."},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3400","article-title":"Drug development in pemphigoid diseases","author":"Bieber","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B274","doi-asserted-by":"publisher","first-page":"e128239","DOI":"10.1172\/jci.insight.128239","article-title":"Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease","volume":"4","author":"Sezin","year":"2019","journal-title":"JCI Insight."},{"key":"B275","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/j.jid.2020.04.025","article-title":"Propranolol is an effective topical and systemic treatment option for experimental epidermolysis bullosa acquisita","volume":"140","author":"St\u00fcssel","year":"2020","journal-title":"J Invest Dermatol."},{"key":"B276","doi-asserted-by":"publisher","first-page":"713312","DOI":"10.3389\/fmed.2021.713312","article-title":"Topical Application of the PI3K\u03b2-selective small molecule inhibitor TGX-221 is an effective treatment option for experimental epidermolysis bullosa acquisita","volume":"8","author":"Zillikens","year":"2021","journal-title":"Front Med."},{"key":"B277","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jama.1940.62810120003010b","article-title":"A case of cold urticaria with an unusual family history","volume":"114","author":"Kile","year":"1940","journal-title":"J Am Med Assoc."},{"key":"B278","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/ng756","article-title":"Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome","volume":"29","author":"Hoffman","year":"2001","journal-title":"Nat Genet."},{"key":"B279","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1073\/pnas.0708616105","article-title":"Mutations in NALP12 cause hereditary periodic fever syndromes","volume":"105","author":"J\u00e9ru","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B280","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1102140","article-title":"Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions","volume":"366","author":"Ombrello","year":"2012","journal-title":"N Engl J Med."},{"key":"B281","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1084\/jem.20141091","article-title":"An inherited mutation in NLRC4 causes autoinflammation in human and mice","volume":"211","author":"Kitamura","year":"2014","journal-title":"J Exp Med."},{"key":"B282","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/art.27342","article-title":"A somatic NLRP3 mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome\/neonatal-onset multisystem inflammatory disease: novel evidence of the role of low-level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases","volume":"62","author":"Ar\u00f3stegui","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B283","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/annrheumdis-2019-215048","article-title":"Classification criteria for autoinflammatory recurrent fevers","volume":"78","author":"Gattorno","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B284","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1007\/s00259-020-04861-4","article-title":"18F-florbetaben positron emission tomography detects cardiac involvement in systemic AA amyloidosis","volume":"47","author":"Papathanasiou","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B285","doi-asserted-by":"publisher","first-page":"E3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B286","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/MOP.0000000000000696","article-title":"New autoinflammatory diseases","volume":"30","author":"Poli","year":"2018","journal-title":"Curr Opin Pediatr."},{"key":"B287","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","article-title":"Secondary, AA, amyloidosis","volume":"44","author":"Papa","year":"2018","journal-title":"Rheum Dis Clin North Am."},{"key":"B288","doi-asserted-by":"publisher","first-page":"e01315","DOI":"10.1128\/JCM.01315-19","article-title":"Third-Generation sequencing in the clinical laboratory: exploring the advantages and challenges of nanopore sequencing","volume":"58","author":"Petersen","year":"2019","journal-title":"J Clin Microbiol."},{"key":"B289","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","article-title":"Pharmacological inhibitors of the NLRP3 inflammasome","volume":"10","author":"Zahid","year":"2019","journal-title":"Front Immunol."},{"key":"B290","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.3390\/molecules26123534","article-title":"Preservation of contractile reserve and diastolic function by inhibiting the NLRP3 inflammasome with OLT1177\u00ae (Dapansutrile) in a mouse model of severe ischemic cardiomyopathy due to non-reperfused anterior wall myocardial infarction","volume":"26","author":"Aliaga","year":"2021","journal-title":"Molecules."},{"key":"B291","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B292","unstructured":"SchnitzlerL Lesions Urticariennes Chroniques Permanentes (Erytheme Petaloide?)1972"},{"key":"B293","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3324\/haematol.2013.084830","article-title":"Schnitzler syndrome: an under-diagnosed clinical entity","volume":"98","author":"Jain","year":"2013","journal-title":"Haematologica."},{"key":"B294","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","article-title":"Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis","volume":"64","author":"Greiner","year":"2018","journal-title":"Clin Chem."},{"key":"B295","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/all.12030","article-title":"How not to miss autoinflammatory diseases masquerading as urticaria","volume":"67","author":"Krause","year":"2012","journal-title":"Allergy."},{"key":"B296","doi-asserted-by":"publisher","first-page":"e6112","DOI":"10.1097\/MD.0000000000006112","article-title":"Delayed effort-induced swelling with myofasciitis and systemic manifestations: a so far unrecognized type of pressure-induced urticaria","volume":"96","author":"Bursztejn","year":"2017","journal-title":"Medicine."},{"key":"B297","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/all.13035","article-title":"Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients","volume":"72","author":"Gusdorf","year":"2017","journal-title":"Allergy."},{"key":"B298","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MD.0b013e3181943f5e","article-title":"Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature","volume":"88","author":"Kieffer","year":"2009","journal-title":"Medicine."},{"key":"B299","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s10067-020-05501-w","article-title":"Efficacy of interleukin-1 blockade in Schnitzler's syndrome without detectable monoclonal gammopathy: a case-based review","volume":"40","author":"Bixio","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B300","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12891-021-04120-z","article-title":"A case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab","volume":"22","author":"Fujita","year":"2021","journal-title":"BMC Musculoskelet Disord."},{"key":"B301","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.semarthrit.2020.05.002","article-title":"Efficacy and safety of canakinumab treatment in schnitzler syndrome: a systematic literature review","volume":"50","author":"Betrains","year":"2020","journal-title":"Semin Arthritis Rheum."},{"key":"B302","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1016\/j.jaip.2021.01.024","article-title":"Tocilizumab treatment in patients with Schnitzler syndrome: an open-label study","volume":"9","author":"Bonnekoh","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B303","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semarthrit.2007.04.001","article-title":"Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment","volume":"37","author":"de Koning","year":"2007","journal-title":"Semin Arthritis Rheum."},{"key":"B304","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2008-02-138156","article-title":"AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome","volume":"112","author":"Wechalekar","year":"2008","journal-title":"Blood."},{"key":"B305","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2119\/molmed.2011.00039","article-title":"Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes","volume":"17","author":"Bodar","year":"2011","journal-title":"Mol Med."},{"key":"B306","doi-asserted-by":"crossref","first-page":"704","DOI":"10.55563\/clinexprheumatol\/1r3i7i","article-title":"Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation","volume":"39","author":"Paladini","year":"2021","journal-title":"Clin Exp Rheumatol."},{"key":"B307","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol."},{"key":"B308","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1177\/0961203318777103","article-title":"Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark","volume":"27","author":"Petersen","year":"2018","journal-title":"Lupus."},{"key":"B309","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jaad.2010.02.008","article-title":"Quality of life in cutaneous lupus erythematosus","volume":"64","author":"Klein","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B310","first-page":"81","article-title":"Cutaneous lupus erythematosus: current and future pathogenesis-directed therapies","volume":"93","author":"Little","year":"2020","journal-title":"Yale J Biol Med."},{"key":"B311","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol."},{"key":"B312","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1001\/jamadermatol.2020.1698","article-title":"Creation and validation of classification criteria for discoid lupus erythematosus","volume":"156","author":"Elman","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B313","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/art.41480","article-title":"Expert perspective: an evidence-based approach to refractory cutaneous lupus erythematosus","volume":"72","author":"Borucki","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B314","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/bjd.17536","article-title":"The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria","volume":"180","author":"Concha","year":"2019","journal-title":"Br J Dermatol."},{"key":"B315","first-page":"782","article-title":"The diagnostic associations of patients with antinuclear antibodies referred to a community rheumatologist","volume":"16","author":"Shiel","year":"1989","journal-title":"J Rheumatol."},{"key":"B316","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/acr.23916","article-title":"Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the american college of rheumatology and\/or systemic lupus international collaborating clinics criteria for systemic lupus erythematosus","volume":"71","author":"Tarazi","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B317","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1515\/CCLM.2001.031","article-title":"Autoantibodies associated with rheumatic diseases","volume":"39","author":"Griesmacher","year":"2001","journal-title":"Clin Chem Lab Med."},{"key":"B318","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/jcp.53.6.424","article-title":"The use of laboratory tests in the diagnosis of SLE","volume":"53","author":"Egner","year":"2000","journal-title":"J Clin Pathol."},{"key":"B319","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/0961203316670731","article-title":"Biological therapies in the treatment of cutaneous lupus erythematosus","volume":"26","author":"Presto","year":"2017","journal-title":"Lupus."},{"key":"B320","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/acr2.11338","article-title":"Journal club: efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomized, multicenter, placebo-controlled, phase 3 trial","volume":"3","author":"Rubio","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"B321","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis","volume":"177","author":"Chasset","year":"2017","journal-title":"Br J Dermatol."},{"key":"B322","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jaad.2010.08.011","article-title":"Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus","volume":"65","author":"Gammon","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B323","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1756-185X.2011.01665.x","article-title":"Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus","volume":"15","author":"Islam","year":"2012","journal-title":"Int J Rheum Dis."},{"key":"B324","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/archderm.1991.04510010083008","article-title":"Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis","volume":"127","author":"Callen","year":"1991","journal-title":"Arch Dermatol."},{"key":"B325","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000441054","article-title":"Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature","volume":"232","author":"Klebes","year":"2016","journal-title":"Dermatology."},{"key":"B326","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","article-title":"Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine","volume":"127","author":"Ruzicka","year":"1992","journal-title":"Br J Dermatol."},{"key":"B327","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jaad.2016.01.054","article-title":"Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients","volume":"74","author":"Fennira","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"B328","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/RHU.0000000000001160","article-title":"Thalidomide and lenalidomide for refractory systemic\/cutaneous lupus erythematosus Treatment: a narrative review of literature for clinical practice","volume":"27","author":"Yuki","year":"2021","journal-title":"J Clin Rheumatol."},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.2181","author":"Werth","year":"2022","journal-title":"Effect of Iberdomide on Cutaneous Manifestations in Systemic Lupus Erythematosus: Results of a 24-Week, Placebo-Controlled, Phase 2 Study"},{"key":"B330","doi-asserted-by":"publisher","first-page":"eabf8442","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Transl Med."},{"key":"B331","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet."},{"key":"B332","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun."},{"key":"B333","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5743","author":"Werth","year":"2022","journal-title":"OP0193 BIIB059, a Humanized Monoclonal Antibody Targeting BDCA2 on Plasmacytoid Dendritic Cells (PDC), Shows Dose-Related Efficacy in the Phase 2 LILAC Study in Patients (PTS) With Active Cutaneous Lupus Erythematosus (CLE)"},{"key":"B334","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","article-title":"Dermatomyositis: current concepts","volume":"36","author":"Bogdanov","year":"2018","journal-title":"Clin Dermatol."},{"key":"B335","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12016-017-8652-1","article-title":"Cutaneous manifestations of dermatomyositis: a comprehensive review","volume":"53","author":"Mainetti","year":"2017","journal-title":"Clin Rev Allergy Immunol."},{"key":"B336","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/01.bor.0000179949.65895.53","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"17","author":"Fathi","year":"2005","journal-title":"Curr Opin Rheumatol."},{"key":"B337","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B338","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B339","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaad.2017.12.074","article-title":"Dermatomyositis: a diagnostic dilemma","volume":"79","author":"Da Silva","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B340","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","article-title":"Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease","volume":"79","author":"Patel","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B341","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaad.2004.04.007","article-title":"Collagen vascular diseases","volume":"51","author":"Callen","year":"2004","journal-title":"J Am Acad Dermatol."},{"key":"B342","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08922-4.","article-title":"Autoantibody markers of increased risk of malignancy in patients with dermatomyositis","author":"Marzecka","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B343","doi-asserted-by":"publisher","first-page":"e22978","DOI":"10.7759\/cureus.22978","article-title":"The role of myositis-specific autoantibodies in the dermatomyositis spectrum","volume":"14","author":"Marasandra Ramesh","year":"2022","journal-title":"Cureus."},{"key":"B344","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0190-9622(98)70496-7","article-title":"Dermatomyositis: a dermatology-based case series","volume":"38","author":"Dawkins","year":"1998","journal-title":"J Am Acad Dermatol."},{"key":"B345","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40257-013-0028-6","article-title":"Cutaneous dermatomyositis: an updated review of treatment options and internal associations","volume":"14","author":"Femia","year":"2013","journal-title":"Am J Clin Dermatol."},{"key":"B346","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","article-title":"Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus","volume":"138","author":"Pelle","year":"2002","journal-title":"Arch Dermatol."},{"key":"B347","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/09546630310018509","article-title":"Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study","volume":"15","author":"Hollar","year":"2004","journal-title":"J Dermatolog Treat."},{"key":"B348","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5021\/ad.2011.23.3.348","article-title":"Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus","volume":"23","author":"Kim","year":"2011","journal-title":"Ann Dermatol."},{"key":"B349","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B350","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-4362.2002.01409.x","article-title":"Cutaneous involvement of dermatomyositis can respond to dapsone therapy","volume":"41","author":"Cohen","year":"2002","journal-title":"Int J Dermatol."},{"key":"B351","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1085-5629(98)80019-9","article-title":"Thalidomide and its impact in dermatology","volume":"17","author":"Stirling","year":"1998","journal-title":"Semin Cutan Med Surg."},{"key":"B352","unstructured":"Corbus Pharmaceuticals Announces Topline Results From DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis2021"},{"key":"B353","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjd.18096","article-title":"Developing classification criteria for skin-predominant dermatomyositis: the delphi process","volume":"182","author":"Concha","year":"2020","journal-title":"Br J Dermatol."},{"key":"B354","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology."},{"key":"B355","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11926-020-00943-2","article-title":"Promising and upcoming treatments in myositis","volume":"22","author":"Smith","year":"2020","journal-title":"Curr Rheumatol Rep."},{"key":"B356","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/qjmed\/hcp174","article-title":"Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study","volume":"103","author":"Nihtyanova","year":"2010","journal-title":"QJM."},{"key":"B357","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","volume":"69","author":"Hao","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B358","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/1756-185X.13438","article-title":"The impact of systemic sclerosis on health-related quality of life assessed by SF-36: a systematic review and meta-analysis","volume":"21","author":"Li","year":"2018","journal-title":"Int J Rheum Dis."},{"key":"B359","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-019-1842-x","article-title":"Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B360","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1093\/rheumatology\/keaa827","article-title":"Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants","volume":"60","author":"van Leeuwen","year":"2021","journal-title":"Rheumatology."},{"key":"B361","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00296-013-2844-7","article-title":"The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary raynaud's phenomenon","volume":"33","author":"Pavlov-Dolijanovic","year":"2013","journal-title":"Rheumatol Int."},{"key":"B362","doi-asserted-by":"publisher","first-page":"101428","DOI":"10.1016\/j.berh.2019.101428","article-title":"Very early systemic sclerosis","volume":"33","author":"Bellando-Randone","year":"2019","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B363","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar4457","article-title":"Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis","volume":"16","author":"Kill","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B364","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.autrev.2016.04.004","article-title":"Antibodies against angiotensin II type 1 receptor (AT1R) and endothelin receptor type A (ETAR) in systemic sclerosis (SSc)-response","volume":"15","author":"Riemekasten","year":"2016","journal-title":"Autoimmun Rev."},{"key":"B365","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B366","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"B367","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"B368","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/RHU.0b013e31819dbe83","article-title":"Unmet patient needs in systemic sclerosis","volume":"15","author":"Rubenzik","year":"2009","journal-title":"J Clin Rheumatol."},{"key":"B369","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12891-017-1603-4","article-title":"Patients' views and needs about systemic sclerosis and its management: a qualitative interview study","volume":"18","author":"Mouthon","year":"2017","journal-title":"BMC Musculoskelet Disord."},{"key":"B370","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"B371","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B372","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA."},{"key":"B373","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: a possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"Br J Dermatol."},{"key":"B374","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.13013","article-title":"Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol."},{"key":"B375","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The \u2018psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol."},{"key":"B376","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1038\/s41467-019-11952-w","article-title":"Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line","volume":"10","author":"Vorobyev","year":"2019","journal-title":"Nat Commun."},{"key":"B377","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B378","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B379","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jaad.2019.06.1300","article-title":"Racial characteristics of alopecia areata in the United States","volume":"83","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B380","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/1346-8138.16191","article-title":"Retrospective analysis of the clinical characteristics and patient-reported outcomes in vulval lichen planus: results from a single-center study","volume":"48","author":"Boch","year":"2021","journal-title":"J Dermatol."},{"key":"B381","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3389\/fimmu.2019.01559","article-title":"the risk of pulmonary embolism in patients with pemphigus: a population-based large-scale longitudinal study","volume":"10","author":"Kridin","year":"2019","journal-title":"Front Immunol."},{"key":"B382","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/jdv.17107","article-title":"Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the schleswig-holstein registry of autoimmune bullous diseases","volume":"35","author":"van Beek","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B383","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4168\/aair.2021.13.4.545","article-title":"Autoimmune diseases are linked to type iib autoimmune chronic spontaneous urticaria","volume":"13","author":"Kolkhir","year":"2021","journal-title":"Allergy Asthma Immunol Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.875492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T14:47:05Z","timestamp":1675781225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.875492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":383,"alternative-id":["10.3389\/fmed.2022.875492"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.875492","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"875492"}}